A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer
Solid Tumor, Glioblastoma, Non-small Cell Lung Cancer
About this trial
This is an interventional treatment trial for Solid Tumor
Eligibility Criteria
Inclusion Criteria:
- Have histologically confirmed solid cancer that is locally advanced and metastatic and available standard treatment options have been exhausted
- Have adequate organ function
- ECOG PS 0-1
Dose Escalation:
- Have measurable or non- measurable disease per RECIST criteria v1.1 or RANO
- Any solid tumor with EGFR and / or HER2 aberration
Dose Expansion:
- Have measurable disease per RECIST criteria v1.1 for solid tumor (excluding primary brain tumor) or RANO (for glioblastoma)
- Cohort A: Non-small cell lung cancer (NSCLC)
- Cohort B: HER2 positive breast cancer
- Cohort C: Recurrent or refractory glioblastoma
- Cohort D: Other solid tumors with EGFR or HER2 aberrations
Exclusion Criteria:
- Non-stable brain metastases
- Have significant cardiovascular disorder
- Have not recovered from prior cancer treatment
- A serious illness or medical condition
Sites / Locations
- Tennessee OncologyRecruiting
- University of Texas MD Anderson Cancer CenterRecruiting
- CLCC Gustave RoussyRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Experimental
Experimental
Experimental
Experimental
Experimental
TAS2940 Dose Escalation
Dose Expansion Non-small Cell Lung Cancer
Dose Expansion Breast Cancer
Dose Expansion Gliblastoma
Dose Expansion Solid tumors
Dose escalation will assess the safety and determine the maximum tolerated dose, the recommended phase 2 dose and the recommended dosing regimen of TAS2940 administered orally.
Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations
Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.
Dose expansion will assess preliminary anti-tumor activity in select solid tumors characterized by HER2 or EGFR aberrations.